董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Robert W. Overell | 男 | Director, President and Chief Executive Officer | 61 | 138.05万美元 | 未持股 | 2017-04-13 |
| Paul H. Johnson | -- | Director | 74 | 13.18万美元 | 未持股 | 2017-04-13 |
| Michelle Griffin | 女 | Director | 51 | 9.43万美元 | 未持股 | 2017-04-13 |
| John A. Schmidt, Jr. | 男 | Director | 66 | 17.42万美元 | 未持股 | 2017-04-13 |
| Brian G. Atwood | 男 | Director | 64 | 12.05万美元 | 未持股 | 2017-04-13 |
| Peggy V. Phillips | 女 | Director | 63 | 7.40万美元 | 未持股 | 2017-04-13 |
| Steven Gillis | 男 | Director, Chairman of the Board | 63 | 16.02万美元 | 未持股 | 2017-04-13 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Robert W. Overell | 男 | Director, President and Chief Executive Officer | 61 | 138.05万美元 | 未持股 | 2017-04-13 |
| Michael Houston | 男 | Chief Scientific Officer | 54 | 61.46万美元 | 未持股 | 2017-04-13 |
| Shing Yin Tsui | 女 | Senior Vice President of Finance and Secretary | 46 | 57.31万美元 | 未持股 | 2017-04-13 |
| Gordon Brandt | 男 | Chief Medical Officer | 57 | 未披露 | 未持股 | 2017-04-13 |
董事简历
中英对照 | 中文 | 英文- Robert W. Overell
-
Robert W. Overell自2006年起担任总裁和董事；自2009年起担任首席执行官。公司于2008年进行首次机构融资，在此之前Overell曾担任Foundation BioVentures LLC（为初创公司提供信息和咨询服务）总裁。在此之前，Overell曾于1996年到2005年担任Frazier Healthcare Ventures顾问、资本合伙人，后担任普通合伙人，参与6亿多美元的风险资本并对初创生物技术公司进行6000万美元的投资。Overell曾担任多个公司董事，包括从1998年到2002年担任Array Biopharma Inc. NASDAQ：ARRY；1999年到2005年担任XenoPort, Inc. （NASDAQ：XNPT）（1999年联合创立）董事；2004年到2005年担任Chimerix, Inc. （NASDAQ：CMRX）董事。Overell帮助创立Immunex Corporation基因疗法分离公司Targeted Genetics Corp.，1992年到1996年领导产品开发和基因传递项目。Overell于1984年加入Immunex Corporation，领导细胞和分子生物学项目。他还领导世界上第一个人类免疫缺陷病毒基因治疗试验的开发，1991年通过National Institutes of Health and the FDA的Recombinant DNA顾问委员会认证。Overell持有the University of Newcastle-upon-Tyne生物科学理学学士学位；英国the Institute of Cancer Research, University of London生物化学博士学位。
Robert W. Overell, Ph.D. has served as our president and member of our Board since 2006 and our chief executive officer since 2009. Prior to our first institutional financing in 2008 Dr. Overell was president of Foundation BioVentures LLC, which provided company formation and consulting services to startup companies, including us. Prior to that, Dr. Overell was a consultant, venture partner, then general partner with Frazier Healthcare Ventures from 1996 to 2005 where he participated in raising over $600 million of venture capital and invested over $60 million in early-stage biotechnology companies. Dr. Overell has served on numerous corporate boards, including Array Biopharma Inc. NASDAQ:ARRY from 1998 to 2002 XenoPort, Inc. (NASDAQ:XNPT), which he co-founded in 1999 from 1999 to 2005 and Chimerix, Inc. (NASDAQ: CMRX) from 2004 to 2005. Dr. Overell helped found Immunex Corporation’s gene therapy spinout, Targeted Genetics Corp., where he led product development and gene delivery programs from 1992 to 1996. Dr. Overell joined Immunex Corporation in 1984 where he led programs in cell and molecular biology. He also led development of the first human immunodeficiency virus gene therapy trial in the world, which was approved by the Recombinant DNA Advisory Committee of the National Institutes of Health and the FDA in 1991. Dr. Overell obtained a B.Sc. in biological sciences from the University of Newcastle-upon-Tyne and a Ph.D. in biochemistry from the Institute of Cancer Research, University of London, United Kingdom. - Robert W. Overell自2006年起担任总裁和董事；自2009年起担任首席执行官。公司于2008年进行首次机构融资，在此之前Overell曾担任Foundation BioVentures LLC（为初创公司提供信息和咨询服务）总裁。在此之前，Overell曾于1996年到2005年担任Frazier Healthcare Ventures顾问、资本合伙人，后担任普通合伙人，参与6亿多美元的风险资本并对初创生物技术公司进行6000万美元的投资。Overell曾担任多个公司董事，包括从1998年到2002年担任Array Biopharma Inc. NASDAQ：ARRY；1999年到2005年担任XenoPort, Inc. （NASDAQ：XNPT）（1999年联合创立）董事；2004年到2005年担任Chimerix, Inc. （NASDAQ：CMRX）董事。Overell帮助创立Immunex Corporation基因疗法分离公司Targeted Genetics Corp.，1992年到1996年领导产品开发和基因传递项目。Overell于1984年加入Immunex Corporation，领导细胞和分子生物学项目。他还领导世界上第一个人类免疫缺陷病毒基因治疗试验的开发，1991年通过National Institutes of Health and the FDA的Recombinant DNA顾问委员会认证。Overell持有the University of Newcastle-upon-Tyne生物科学理学学士学位；英国the Institute of Cancer Research, University of London生物化学博士学位。
- Robert W. Overell, Ph.D. has served as our president and member of our Board since 2006 and our chief executive officer since 2009. Prior to our first institutional financing in 2008 Dr. Overell was president of Foundation BioVentures LLC, which provided company formation and consulting services to startup companies, including us. Prior to that, Dr. Overell was a consultant, venture partner, then general partner with Frazier Healthcare Ventures from 1996 to 2005 where he participated in raising over $600 million of venture capital and invested over $60 million in early-stage biotechnology companies. Dr. Overell has served on numerous corporate boards, including Array Biopharma Inc. NASDAQ:ARRY from 1998 to 2002 XenoPort, Inc. (NASDAQ:XNPT), which he co-founded in 1999 from 1999 to 2005 and Chimerix, Inc. (NASDAQ: CMRX) from 2004 to 2005. Dr. Overell helped found Immunex Corporation’s gene therapy spinout, Targeted Genetics Corp., where he led product development and gene delivery programs from 1992 to 1996. Dr. Overell joined Immunex Corporation in 1984 where he led programs in cell and molecular biology. He also led development of the first human immunodeficiency virus gene therapy trial in the world, which was approved by the Recombinant DNA Advisory Committee of the National Institutes of Health and the FDA in 1991. Dr. Overell obtained a B.Sc. in biological sciences from the University of Newcastle-upon-Tyne and a Ph.D. in biochemistry from the Institute of Cancer Research, University of London, United Kingdom.
- Paul H. Johnson
-
Paul H. Johnson自2007年起担任公司董事。Johnson从2007年到2015年担任公司首席科技官。Johnson从2003年到2007年担任Nastech Pharmaceutical Company, Inc.研发高级副总裁和首席科技官；2000年到2003年担任EpiGenx Pharmaceuticals, Inc.研发副总裁和首席科技官；自2014年起担任Next Frontier Biosciences执行副总裁和首席科技官。Johnson持有布法罗State University of New York分子生物学理学学士学位；Roswell Park Cancer Institute SUNY生物化学博士学位。
Paul H. Johnson, Ph.D. has served as a member of our Board since 2007. From 2007 to 2015 Dr. Johnson served as our chief scientific officer. From 2003 to 2007 Dr. Johnson was senior vice president, research and development, and chief scientific officer of Nastech Pharmaceutical Company, Inc. From 2000 to 2003 Dr. Johnson served as vice president, research and development, and chief scientific officer of EpiGenx Pharmaceuticals, Inc. Since 2014 Dr. Johnson has been executive vice president and chief scientific officer of Next Frontier Biosciences. Dr. Johnson received a B.S. in molecular biology from the State University of New York, Buffalo and a Ph.D. in biochemistry from Roswell Park Cancer Institute SUNY. - Paul H. Johnson自2007年起担任公司董事。Johnson从2007年到2015年担任公司首席科技官。Johnson从2003年到2007年担任Nastech Pharmaceutical Company, Inc.研发高级副总裁和首席科技官；2000年到2003年担任EpiGenx Pharmaceuticals, Inc.研发副总裁和首席科技官；自2014年起担任Next Frontier Biosciences执行副总裁和首席科技官。Johnson持有布法罗State University of New York分子生物学理学学士学位；Roswell Park Cancer Institute SUNY生物化学博士学位。
- Paul H. Johnson, Ph.D. has served as a member of our Board since 2007. From 2007 to 2015 Dr. Johnson served as our chief scientific officer. From 2003 to 2007 Dr. Johnson was senior vice president, research and development, and chief scientific officer of Nastech Pharmaceutical Company, Inc. From 2000 to 2003 Dr. Johnson served as vice president, research and development, and chief scientific officer of EpiGenx Pharmaceuticals, Inc. Since 2014 Dr. Johnson has been executive vice president and chief scientific officer of Next Frontier Biosciences. Dr. Johnson received a B.S. in molecular biology from the State University of New York, Buffalo and a Ph.D. in biochemistry from Roswell Park Cancer Institute SUNY.
- Michelle Griffin
-
Michelle Griffin自2016年2月起担任公司董事。Griffin如今通过自己的公司Pacific Biotechnology Consulting Group为生物技术公司和董事会提供咨询服务。Griffin从2012年到2014年担任Polynoma LLC董事。Griffin从2011年1月到2013年3月担任OncoGenex Pharmaceuticals Inc.运营执行副总裁和首席财务官。Griffin之前曾于2004年5月到2011年1月担任OncoGenex Pharmaceuticals Inc.董事。Griffin从2006年2月到2010年10月（被Emergent BioSolutions, Inc.收购）担任Trubion Pharmaceuticals, Inc.（一家生物制药公司）代理首席主管、高级副总裁和首席运营官；2005年8月到2006年1月担任Dendreon Corporation（一家生物制药公司）高级副总裁和首席财务官。她从1995年3月到2005年7月在Corixa Corporation（一家生物技术公司）任职，1997年到2005年（Corixa Corporation于2005年被GlaxoSmithKline plc.收购）担任首席财务官；在此之前她曾在The Boeing Company担任多个金融和战略规划职位。她持有Seattle University会计研究生证书和工商管理硕士学位；George Mason University统计数据和营销理学学士学位；已通过注册会计师考试。
Michelle Griffin has served as a director since the completion of the 2017 merger. Ms. Griffin serves as a member of the Board of Directors and as Chair of the Audit Committee for publicly traded companies Chinook Therapeutics, Inc. since October 2020 Adaptive Biotechnologies Corporation since March 2019 and HTG Molecular Diagnostics, Inc. since August 2018. From 2013 to 2020 Ms. Griffin served as the Principal of Pacific Biotechnology Consulting Group, a firm providing consulting services to biotechnology companies and their Boards of Directors. Ms. Griffin previously served as a member of the Board of Directors and as Chair of the Audit Committee for publicly traded companies PhaseRx, Inc. from 2016 until its acquisition by Roivant Sciences GmbH in 2018 OncoGenex Pharmaceuticals, Inc. from 2008 to 2011 and Sonus Pharmaceuticals, Inc. subsequently acquired by OncoGenex from 2004 to 2008. Ms. Griffin served from January 2011 to March 2013 as Executive Vice President, Operations and Chief Financial Officer of OncoGenex Pharmaceuticals, Inc. During various periods from 1997 to 2011 she served in the capacity of Chief Financial Officer for Trubion Pharmaceuticals, Inc., Dendreon Corporation and Corixa Corporation. Ms. Griffin earned a B.S. in marketing from George Mason University and an M.B.A. with a specialization in finance and international business from Seattle University. - Michelle Griffin自2016年2月起担任公司董事。Griffin如今通过自己的公司Pacific Biotechnology Consulting Group为生物技术公司和董事会提供咨询服务。Griffin从2012年到2014年担任Polynoma LLC董事。Griffin从2011年1月到2013年3月担任OncoGenex Pharmaceuticals Inc.运营执行副总裁和首席财务官。Griffin之前曾于2004年5月到2011年1月担任OncoGenex Pharmaceuticals Inc.董事。Griffin从2006年2月到2010年10月（被Emergent BioSolutions, Inc.收购）担任Trubion Pharmaceuticals, Inc.（一家生物制药公司）代理首席主管、高级副总裁和首席运营官；2005年8月到2006年1月担任Dendreon Corporation（一家生物制药公司）高级副总裁和首席财务官。她从1995年3月到2005年7月在Corixa Corporation（一家生物技术公司）任职，1997年到2005年（Corixa Corporation于2005年被GlaxoSmithKline plc.收购）担任首席财务官；在此之前她曾在The Boeing Company担任多个金融和战略规划职位。她持有Seattle University会计研究生证书和工商管理硕士学位；George Mason University统计数据和营销理学学士学位；已通过注册会计师考试。
- Michelle Griffin has served as a director since the completion of the 2017 merger. Ms. Griffin serves as a member of the Board of Directors and as Chair of the Audit Committee for publicly traded companies Chinook Therapeutics, Inc. since October 2020 Adaptive Biotechnologies Corporation since March 2019 and HTG Molecular Diagnostics, Inc. since August 2018. From 2013 to 2020 Ms. Griffin served as the Principal of Pacific Biotechnology Consulting Group, a firm providing consulting services to biotechnology companies and their Boards of Directors. Ms. Griffin previously served as a member of the Board of Directors and as Chair of the Audit Committee for publicly traded companies PhaseRx, Inc. from 2016 until its acquisition by Roivant Sciences GmbH in 2018 OncoGenex Pharmaceuticals, Inc. from 2008 to 2011 and Sonus Pharmaceuticals, Inc. subsequently acquired by OncoGenex from 2004 to 2008. Ms. Griffin served from January 2011 to March 2013 as Executive Vice President, Operations and Chief Financial Officer of OncoGenex Pharmaceuticals, Inc. During various periods from 1997 to 2011 she served in the capacity of Chief Financial Officer for Trubion Pharmaceuticals, Inc., Dendreon Corporation and Corixa Corporation. Ms. Griffin earned a B.S. in marketing from George Mason University and an M.B.A. with a specialization in finance and international business from Seattle University.
- John A. Schmidt, Jr.
-
John A. Schmidt, Jr.，他一直担任我们的高级副总裁兼首席科学官（2008年9月加入我们以来）。从2004年8月到2008年9月，他曾担任副总裁兼探索研究助理董事、赛诺菲-安万特全球发现领导团队的美国成员，在那里他也负责中国生物治疗药物、外部创新、发现项目的举措。2000年至2004年，他曾担任Aventis公司的副总裁、呼吸和风湿性关节炎疾病集团的主管。
John A. Schmidt, Jr., M.D. has served as a member of our Board since 2010. From 2008 to 2009 Dr. Schmidt served as the chief scientific officer of Alnylam Pharmaceuticals, Inc., and prior to that, from 2004 to 2008 he was vice president and sole U.S. member of the Sanofi-Aventis U.S. LLC’s Global Discovery Leadership Team where he was responsible for the biotherapeutics, external innovation, and China discovery initiatives. From 2000 to 2004 Dr. Schmidt served as vice president and head of the respiratory and rheumatoid arthritis disease group of legacy Aventis, during which time he advanced more than 15 new chemical entities into preclinical and clinical development. From 1990 to 2000 Dr. Schmidt served as senior director of immunology and rheumatology at Merck Research Laboratories. Dr. Schmidt received a B.S. in biology from St. Joseph’s University in Philadelphia and an M.D. from the University of Pennsylvania. - John A. Schmidt, Jr.，他一直担任我们的高级副总裁兼首席科学官（2008年9月加入我们以来）。从2004年8月到2008年9月，他曾担任副总裁兼探索研究助理董事、赛诺菲-安万特全球发现领导团队的美国成员，在那里他也负责中国生物治疗药物、外部创新、发现项目的举措。2000年至2004年，他曾担任Aventis公司的副总裁、呼吸和风湿性关节炎疾病集团的主管。
- John A. Schmidt, Jr., M.D. has served as a member of our Board since 2010. From 2008 to 2009 Dr. Schmidt served as the chief scientific officer of Alnylam Pharmaceuticals, Inc., and prior to that, from 2004 to 2008 he was vice president and sole U.S. member of the Sanofi-Aventis U.S. LLC’s Global Discovery Leadership Team where he was responsible for the biotherapeutics, external innovation, and China discovery initiatives. From 2000 to 2004 Dr. Schmidt served as vice president and head of the respiratory and rheumatoid arthritis disease group of legacy Aventis, during which time he advanced more than 15 new chemical entities into preclinical and clinical development. From 1990 to 2000 Dr. Schmidt served as senior director of immunology and rheumatology at Merck Research Laboratories. Dr. Schmidt received a B.S. in biology from St. Joseph’s University in Philadelphia and an M.D. from the University of Pennsylvania.
- Brian G. Atwood
-
自公司成立初期，Brian G. Atwood担任我们董事会的成员。1999年他创办该公司，目前他担任Versant Ventures董事总经理，一家关注医疗健康风险资本公司。成立Versant Ventures之前，他担任Brentwood Associates普通合伙人，一家风险投资公司。他在几家制药和生物技术公司的董事会任职，包括Atreca , Five Prime Therapeutics, NASDAQ： FPRX, Immune Design Corp., Groove Biopharma Corporation （前身是 Mirina Corporation）， OpGen, PhaseRx, Spark Diagnostics，和 Veracyte。他还在Helicos Biosciences、 Pharmion Corporation、Trius Therapeutics（于2013被收购）和Cadence Pharmaceuticals（于2014被收购）的董事会任职。他拥有加州大学欧文分校生物科学学士学位，戴维斯加州大学生态学硕士学位，哈佛大学的MBA学位。
Brian G. Atwood will serve as our Chairman immediately upon the effective date of this prospectus. Mr. Atwood serves as a Managing Director for Versant Ventures, a healthcare-focused venture capital firm that he co-founded in 1999. In 2015 Mr. Atwood co-founded Cell Design Labs, Inc., a biotechnology company focused on developing human cell engineering technology for the treatment of multiple diseases, including cancer, where he served as President and Chief Executive Officer until 2017 when it was acquired by Gilead Sciences. Mr. Atwood serves on the board of directors of Clovis Oncology, Inc. NASDAQ: CLVS, and Atreca, Inc. (NASDAQ: BCEL), where he is Chairman. He also served on the board of directors of Immune Design Corp. from May 2008 until June 2016 (acquired by Merck in 2019), Veracyte, Inc., from its founding in 2008 until December 2016 OpGen Inc., from July 2007 until December 2017 Five Prime Therapeutics, from 2002 until March 2016 Cadence Pharmaceuticals, Inc. from March 2006 until its acquisition in March 2014 Helicos Biosciences from 2003 until September 2011 Pharmion Corporation from 2000 until its acquisition in March 2008 Trius Therapeutics, Inc. from February 2007 until its acquisition in September 2013 and LWAC from January 2021 until the consummation of its business combination in August 2021. Mr. Atwood holds a B.S. in Biological Sciences from the University of California, Irvine, a M.S. in Ecology from the University of California, Davis, and a M.B.A. from Harvard Business School. - 自公司成立初期，Brian G. Atwood担任我们董事会的成员。1999年他创办该公司，目前他担任Versant Ventures董事总经理，一家关注医疗健康风险资本公司。成立Versant Ventures之前，他担任Brentwood Associates普通合伙人，一家风险投资公司。他在几家制药和生物技术公司的董事会任职，包括Atreca , Five Prime Therapeutics, NASDAQ： FPRX, Immune Design Corp., Groove Biopharma Corporation （前身是 Mirina Corporation）， OpGen, PhaseRx, Spark Diagnostics，和 Veracyte。他还在Helicos Biosciences、 Pharmion Corporation、Trius Therapeutics（于2013被收购）和Cadence Pharmaceuticals（于2014被收购）的董事会任职。他拥有加州大学欧文分校生物科学学士学位，戴维斯加州大学生态学硕士学位，哈佛大学的MBA学位。
- Brian G. Atwood will serve as our Chairman immediately upon the effective date of this prospectus. Mr. Atwood serves as a Managing Director for Versant Ventures, a healthcare-focused venture capital firm that he co-founded in 1999. In 2015 Mr. Atwood co-founded Cell Design Labs, Inc., a biotechnology company focused on developing human cell engineering technology for the treatment of multiple diseases, including cancer, where he served as President and Chief Executive Officer until 2017 when it was acquired by Gilead Sciences. Mr. Atwood serves on the board of directors of Clovis Oncology, Inc. NASDAQ: CLVS, and Atreca, Inc. (NASDAQ: BCEL), where he is Chairman. He also served on the board of directors of Immune Design Corp. from May 2008 until June 2016 (acquired by Merck in 2019), Veracyte, Inc., from its founding in 2008 until December 2016 OpGen Inc., from July 2007 until December 2017 Five Prime Therapeutics, from 2002 until March 2016 Cadence Pharmaceuticals, Inc. from March 2006 until its acquisition in March 2014 Helicos Biosciences from 2003 until September 2011 Pharmion Corporation from 2000 until its acquisition in March 2008 Trius Therapeutics, Inc. from February 2007 until its acquisition in September 2013 and LWAC from January 2021 until the consummation of its business combination in August 2021. Mr. Atwood holds a B.S. in Biological Sciences from the University of California, Irvine, a M.S. in Ecology from the University of California, Davis, and a M.B.A. from Harvard Business School.
- Peggy V. Phillips
-
Peggy V. Phillips，自2006年8月，她担任本公司董事。自2006年至2013年，她在Portola Pharmaceuticals这家生物制药公司担任董事。自2004年，她在Western Wireless这家蜂窝网络运营商担任董事，直至该公司于2005年中旬被Alltel公司收购。自2003年至2011年，她在海军学术基金会（Naval Academy Foundation）担任董事。自1996年至2002年，她在Immunex这家生物技术公司担任董事。自1999年，她担任该公司首席运营官，直至2002年该公司被Amgen公司收购。在Immunex公司任职期间，她负责研究、开发、制造、销售和市场营销方面的事务。她在Enbrel公司担任制药开发方面的高级副总裁和总经理，致力于临床新产品开发和监管事务，还负责产品的发布、销售和市场营销方面的事务。在加盟Immunex公司前，她在Miles Laboratories公司任职。她在爱达荷大学（University of Idaho）获得微生物学学士学位和微生物学硕士学位。
Peggy V. Phillips has been a member of the company's Board since August 2006. Ms. Phillips served on the board of directors of Tekmira Pharmaceuticals from February 2014 to March 2015. Ms. Phillips served on the board of directors of Portola Pharmaceuticals, a biopharmaceutical company, from 2006 to 2013. From 2003 until 2011 Ms. Phillips served on the board of the Naval Academy Foundation. From 1996 until 2002 she served on the board of directors of Immunex Corporation, a biotechnology company, and, from 1999 she served as the Chief Operating Officer until the company was acquired by Amgen in 2002. During her career at Immunex, she held positions of increasing responsibility in research, development, manufacturing, sales and marketing. As Senior Vice President for Pharmaceutical Development and General Manager for Enbrel® from 1994 until 1998 she was responsible for clinical development and regulatory affairs as well as the launch, sales and marketing of the product. Prior to joining Immunex, Ms. Phillips worked at Miles Laboratories. Ms. Phillips holds a B.S. and a M.S. in microbiology from the University of Idaho. - Peggy V. Phillips，自2006年8月，她担任本公司董事。自2006年至2013年，她在Portola Pharmaceuticals这家生物制药公司担任董事。自2004年，她在Western Wireless这家蜂窝网络运营商担任董事，直至该公司于2005年中旬被Alltel公司收购。自2003年至2011年，她在海军学术基金会（Naval Academy Foundation）担任董事。自1996年至2002年，她在Immunex这家生物技术公司担任董事。自1999年，她担任该公司首席运营官，直至2002年该公司被Amgen公司收购。在Immunex公司任职期间，她负责研究、开发、制造、销售和市场营销方面的事务。她在Enbrel公司担任制药开发方面的高级副总裁和总经理，致力于临床新产品开发和监管事务，还负责产品的发布、销售和市场营销方面的事务。在加盟Immunex公司前，她在Miles Laboratories公司任职。她在爱达荷大学（University of Idaho）获得微生物学学士学位和微生物学硕士学位。
- Peggy V. Phillips has been a member of the company's Board since August 2006. Ms. Phillips served on the board of directors of Tekmira Pharmaceuticals from February 2014 to March 2015. Ms. Phillips served on the board of directors of Portola Pharmaceuticals, a biopharmaceutical company, from 2006 to 2013. From 2003 until 2011 Ms. Phillips served on the board of the Naval Academy Foundation. From 1996 until 2002 she served on the board of directors of Immunex Corporation, a biotechnology company, and, from 1999 she served as the Chief Operating Officer until the company was acquired by Amgen in 2002. During her career at Immunex, she held positions of increasing responsibility in research, development, manufacturing, sales and marketing. As Senior Vice President for Pharmaceutical Development and General Manager for Enbrel® from 1994 until 1998 she was responsible for clinical development and regulatory affairs as well as the launch, sales and marketing of the product. Prior to joining Immunex, Ms. Phillips worked at Miles Laboratories. Ms. Phillips holds a B.S. and a M.S. in microbiology from the University of Idaho.
- Steven Gillis
-
Steven Gillis，自2019年1月起担任Takeda的外部董事。在被任命之前，Gillis博士是Shire plc的外部董事。他目前还担任ARCH Venture Partners的董事总经理，Codiak BioSciences, Inc.的外部董事和主席，Homology Medicines, Inc.的外部董事和VBI Vaccines, Inc.的外部董事和主席。他是Corixa Corporation（于2005年被GlaxoSmithKline收购）的创始人兼董事，此前是Immunex Corporation的创始人兼董事。
Steven Gillis,has served as Vbi Vaccines Inc. Chairperson and as a member of Vbi Vaccines Inc. Board since May 2016. Dr. Gillis has served as a member of the board of directors of VBI DE and VBI US since July 2014 and December 2006, respectively. Since 2006, he has been a Managing Director of ARCH Venture Partners, or ARCH, a firm he joined in 2005. Dr. Gillis is focused on the evaluation of new life science technologies and also on the development and growth of ARCH's biotechnology portfolio companies. In addition to serving on Vbi Vaccines Inc. Board, Dr. Gillis currently serves as a director of Takeda Pharmaceutical Co. Ltd. (NYSE: TAK), Homology Medicines, Inc. (NASDAQ: FIXX), Codiak Biosciences, Inc (NASDAQ: CDAK) and served on the Board of Pulmatrix, Inc. (NASDAQ: PULM) until August 2020. Dr. Gillis represents ARCH as a director and serves as Chairperson of a number of ARCH's private biotechnology portfolio companies. Dr. Gillis was a founder and director of Corixa Corporation and served as Chief Executive Officer from its inception and as its Chairperson from 1999 until its acquisition in 2005 by GlaxoSmithKline. Prior to Corixa, Dr. Gillis was a founder and director of Immunex Corp. From 1981 until his departure in 1994, Dr. Gillis served as Immunex's Director of Research and Development, Chief Scientific Officer, and as Chief Executive Officer of Immunex's R&D subsidiary. Dr. Gillis was interim Chief Executive Officer of Immunex Corp. following its majority purchase by American Cyanamid Company and remained a member of the board until 1997. Amgen, Inc. acquired Immunex in 2002.Dr. Gillis is an immunologist by training with over 300 peer-reviewed publications in the areas of molecular and tumor immunology. He is credited as being a pioneer in the field of cytokines and cytokine receptors, directing the development of multiple marketed products including Leukine, (GM-CSF), Prokine (IL-2) and Enbrel (soluble TNF receptor-Fc fusion protein) as well as the regulatory approval of Bexxar (radiolabeled anti- CD20). Dr. Gillis received a B.A. from Williams College and a Ph.D. from Dartmouth College. - Steven Gillis，自2019年1月起担任Takeda的外部董事。在被任命之前，Gillis博士是Shire plc的外部董事。他目前还担任ARCH Venture Partners的董事总经理，Codiak BioSciences, Inc.的外部董事和主席，Homology Medicines, Inc.的外部董事和VBI Vaccines, Inc.的外部董事和主席。他是Corixa Corporation（于2005年被GlaxoSmithKline收购）的创始人兼董事，此前是Immunex Corporation的创始人兼董事。
- Steven Gillis,has served as Vbi Vaccines Inc. Chairperson and as a member of Vbi Vaccines Inc. Board since May 2016. Dr. Gillis has served as a member of the board of directors of VBI DE and VBI US since July 2014 and December 2006, respectively. Since 2006, he has been a Managing Director of ARCH Venture Partners, or ARCH, a firm he joined in 2005. Dr. Gillis is focused on the evaluation of new life science technologies and also on the development and growth of ARCH's biotechnology portfolio companies. In addition to serving on Vbi Vaccines Inc. Board, Dr. Gillis currently serves as a director of Takeda Pharmaceutical Co. Ltd. (NYSE: TAK), Homology Medicines, Inc. (NASDAQ: FIXX), Codiak Biosciences, Inc (NASDAQ: CDAK) and served on the Board of Pulmatrix, Inc. (NASDAQ: PULM) until August 2020. Dr. Gillis represents ARCH as a director and serves as Chairperson of a number of ARCH's private biotechnology portfolio companies. Dr. Gillis was a founder and director of Corixa Corporation and served as Chief Executive Officer from its inception and as its Chairperson from 1999 until its acquisition in 2005 by GlaxoSmithKline. Prior to Corixa, Dr. Gillis was a founder and director of Immunex Corp. From 1981 until his departure in 1994, Dr. Gillis served as Immunex's Director of Research and Development, Chief Scientific Officer, and as Chief Executive Officer of Immunex's R&D subsidiary. Dr. Gillis was interim Chief Executive Officer of Immunex Corp. following its majority purchase by American Cyanamid Company and remained a member of the board until 1997. Amgen, Inc. acquired Immunex in 2002.Dr. Gillis is an immunologist by training with over 300 peer-reviewed publications in the areas of molecular and tumor immunology. He is credited as being a pioneer in the field of cytokines and cytokine receptors, directing the development of multiple marketed products including Leukine, (GM-CSF), Prokine (IL-2) and Enbrel (soluble TNF receptor-Fc fusion protein) as well as the regulatory approval of Bexxar (radiolabeled anti- CD20). Dr. Gillis received a B.A. from Williams College and a Ph.D. from Dartmouth College.
高管简历
中英对照 | 中文 | 英文- Robert W. Overell
Robert W. Overell自2006年起担任总裁和董事；自2009年起担任首席执行官。公司于2008年进行首次机构融资，在此之前Overell曾担任Foundation BioVentures LLC（为初创公司提供信息和咨询服务）总裁。在此之前，Overell曾于1996年到2005年担任Frazier Healthcare Ventures顾问、资本合伙人，后担任普通合伙人，参与6亿多美元的风险资本并对初创生物技术公司进行6000万美元的投资。Overell曾担任多个公司董事，包括从1998年到2002年担任Array Biopharma Inc. NASDAQ：ARRY；1999年到2005年担任XenoPort, Inc. （NASDAQ：XNPT）（1999年联合创立）董事；2004年到2005年担任Chimerix, Inc. （NASDAQ：CMRX）董事。Overell帮助创立Immunex Corporation基因疗法分离公司Targeted Genetics Corp.，1992年到1996年领导产品开发和基因传递项目。Overell于1984年加入Immunex Corporation，领导细胞和分子生物学项目。他还领导世界上第一个人类免疫缺陷病毒基因治疗试验的开发，1991年通过National Institutes of Health and the FDA的Recombinant DNA顾问委员会认证。Overell持有the University of Newcastle-upon-Tyne生物科学理学学士学位；英国the Institute of Cancer Research, University of London生物化学博士学位。
Robert W. Overell, Ph.D. has served as our president and member of our Board since 2006 and our chief executive officer since 2009. Prior to our first institutional financing in 2008 Dr. Overell was president of Foundation BioVentures LLC, which provided company formation and consulting services to startup companies, including us. Prior to that, Dr. Overell was a consultant, venture partner, then general partner with Frazier Healthcare Ventures from 1996 to 2005 where he participated in raising over $600 million of venture capital and invested over $60 million in early-stage biotechnology companies. Dr. Overell has served on numerous corporate boards, including Array Biopharma Inc. NASDAQ:ARRY from 1998 to 2002 XenoPort, Inc. (NASDAQ:XNPT), which he co-founded in 1999 from 1999 to 2005 and Chimerix, Inc. (NASDAQ: CMRX) from 2004 to 2005. Dr. Overell helped found Immunex Corporation’s gene therapy spinout, Targeted Genetics Corp., where he led product development and gene delivery programs from 1992 to 1996. Dr. Overell joined Immunex Corporation in 1984 where he led programs in cell and molecular biology. He also led development of the first human immunodeficiency virus gene therapy trial in the world, which was approved by the Recombinant DNA Advisory Committee of the National Institutes of Health and the FDA in 1991. Dr. Overell obtained a B.Sc. in biological sciences from the University of Newcastle-upon-Tyne and a Ph.D. in biochemistry from the Institute of Cancer Research, University of London, United Kingdom.- Robert W. Overell自2006年起担任总裁和董事；自2009年起担任首席执行官。公司于2008年进行首次机构融资，在此之前Overell曾担任Foundation BioVentures LLC（为初创公司提供信息和咨询服务）总裁。在此之前，Overell曾于1996年到2005年担任Frazier Healthcare Ventures顾问、资本合伙人，后担任普通合伙人，参与6亿多美元的风险资本并对初创生物技术公司进行6000万美元的投资。Overell曾担任多个公司董事，包括从1998年到2002年担任Array Biopharma Inc. NASDAQ：ARRY；1999年到2005年担任XenoPort, Inc. （NASDAQ：XNPT）（1999年联合创立）董事；2004年到2005年担任Chimerix, Inc. （NASDAQ：CMRX）董事。Overell帮助创立Immunex Corporation基因疗法分离公司Targeted Genetics Corp.，1992年到1996年领导产品开发和基因传递项目。Overell于1984年加入Immunex Corporation，领导细胞和分子生物学项目。他还领导世界上第一个人类免疫缺陷病毒基因治疗试验的开发，1991年通过National Institutes of Health and the FDA的Recombinant DNA顾问委员会认证。Overell持有the University of Newcastle-upon-Tyne生物科学理学学士学位；英国the Institute of Cancer Research, University of London生物化学博士学位。
- Robert W. Overell, Ph.D. has served as our president and member of our Board since 2006 and our chief executive officer since 2009. Prior to our first institutional financing in 2008 Dr. Overell was president of Foundation BioVentures LLC, which provided company formation and consulting services to startup companies, including us. Prior to that, Dr. Overell was a consultant, venture partner, then general partner with Frazier Healthcare Ventures from 1996 to 2005 where he participated in raising over $600 million of venture capital and invested over $60 million in early-stage biotechnology companies. Dr. Overell has served on numerous corporate boards, including Array Biopharma Inc. NASDAQ:ARRY from 1998 to 2002 XenoPort, Inc. (NASDAQ:XNPT), which he co-founded in 1999 from 1999 to 2005 and Chimerix, Inc. (NASDAQ: CMRX) from 2004 to 2005. Dr. Overell helped found Immunex Corporation’s gene therapy spinout, Targeted Genetics Corp., where he led product development and gene delivery programs from 1992 to 1996. Dr. Overell joined Immunex Corporation in 1984 where he led programs in cell and molecular biology. He also led development of the first human immunodeficiency virus gene therapy trial in the world, which was approved by the Recombinant DNA Advisory Committee of the National Institutes of Health and the FDA in 1991. Dr. Overell obtained a B.Sc. in biological sciences from the University of Newcastle-upon-Tyne and a Ph.D. in biochemistry from the Institute of Cancer Research, University of London, United Kingdom.
- Michael Houston
Michael Houston于2015年12月被任命为首席科技官。Houston于2014年1月加入公司担任治疗开发副总裁。Houston从2012年到2013年为Solid-Phase Consulting提供咨询服务，专注于以缩氨酸和寡核苷酸为基础的研发活动以及风险投资公司的尽职调查服务。Houston从2009年到2012年担任Marina Biotech, Inc. OTCQB：MRNA化学和配方副总裁，领导小组开发新型氨基酸脂肪和缩氨酸，开发以纳米颗粒为基础的配方，以应付siRNAs and miRNAs。在此之前，Houston曾担任Anchor Therapeutics, Inc. （前身是 Ascent Therapeutics, Inc.，为pepducin钛技术开发化学。分析方法和配方） 临床化学和化学、制造和控制副总裁。Houston从2008年到2009年担任MDRNA, Inc.化学&配方副总裁，监管药物产品处理和管理临床开发。Houston从2004年到2008年在Nastech Pharmaceutical Company Inc.担任多个领导职位，包括化学和配方高级主管。在此之前，Houston还担任Cytovax Biotechnologies, Inc.化学主管和高级科学家，专注于peptide-protein结合疫苗的开发。Houston持有加拿大安大略the University of Waterloo化学理学学士学位；生物有机化学博士学位；在the Protein Engineering Network of Centres of Excellence at the University of Alberta完成了基因工程博士后奖学金学习。
Michael Houston, Ph.D. was appointed as the chief scientific officer in December 2015. Dr. Houston joined us as vice president, therapeutics development, in January 2014. From 2012 to 2013 Dr. Houston provided consulting services at Solid-Phase Consulting, focused on peptide and oligonucleotide-based research and development activities as well as due diligence services for venture capital firms. From 2009 to 2012 Dr. Houston served as vice president of chemistry and formulations for Marina Biotech, Inc. OTCQB: MRNA, where he led a team developing novel amino acid-based lipids and peptides developing nanoparticle-based formulations to deliver siRNAs and miRNAs. Prior to that, Dr. Houston served as vice president of preclinical chemistry and chemistry, manufacturing and control for Anchor Therapeutics, Inc. (previously Ascent Therapeutics, Inc.) developing chemistry, analytical methods and formulations for the pepducin peptide technology. From 2008 to 2009 Dr. Houston served as vice president, chemistry & formulations at MDRNA, Inc., overseeing drug product processes and managing preclinical development. From 2004 to 2008 Dr. Houston served at Nastech Pharmaceutical Company Inc. in various leadership positions including senior director of chemistry and formulations. Prior to that, Dr. Houston has also served at Cytovax Biotechnologies, Inc. as director of chemistry and senior scientist, focusing on the development of peptide-protein conjugate vaccines. Dr. Houston received a B.Sc. in chemistry and a Ph.D. in bio-organic chemistry from the University of Waterloo, Ontario, Canada, and completed his post-doctoral fellowships in protein engineering at the Protein Engineering Network of Centres of Excellence at the University of Alberta.- Michael Houston于2015年12月被任命为首席科技官。Houston于2014年1月加入公司担任治疗开发副总裁。Houston从2012年到2013年为Solid-Phase Consulting提供咨询服务，专注于以缩氨酸和寡核苷酸为基础的研发活动以及风险投资公司的尽职调查服务。Houston从2009年到2012年担任Marina Biotech, Inc. OTCQB：MRNA化学和配方副总裁，领导小组开发新型氨基酸脂肪和缩氨酸，开发以纳米颗粒为基础的配方，以应付siRNAs and miRNAs。在此之前，Houston曾担任Anchor Therapeutics, Inc. （前身是 Ascent Therapeutics, Inc.，为pepducin钛技术开发化学。分析方法和配方） 临床化学和化学、制造和控制副总裁。Houston从2008年到2009年担任MDRNA, Inc.化学&配方副总裁，监管药物产品处理和管理临床开发。Houston从2004年到2008年在Nastech Pharmaceutical Company Inc.担任多个领导职位，包括化学和配方高级主管。在此之前，Houston还担任Cytovax Biotechnologies, Inc.化学主管和高级科学家，专注于peptide-protein结合疫苗的开发。Houston持有加拿大安大略the University of Waterloo化学理学学士学位；生物有机化学博士学位；在the Protein Engineering Network of Centres of Excellence at the University of Alberta完成了基因工程博士后奖学金学习。
- Michael Houston, Ph.D. was appointed as the chief scientific officer in December 2015. Dr. Houston joined us as vice president, therapeutics development, in January 2014. From 2012 to 2013 Dr. Houston provided consulting services at Solid-Phase Consulting, focused on peptide and oligonucleotide-based research and development activities as well as due diligence services for venture capital firms. From 2009 to 2012 Dr. Houston served as vice president of chemistry and formulations for Marina Biotech, Inc. OTCQB: MRNA, where he led a team developing novel amino acid-based lipids and peptides developing nanoparticle-based formulations to deliver siRNAs and miRNAs. Prior to that, Dr. Houston served as vice president of preclinical chemistry and chemistry, manufacturing and control for Anchor Therapeutics, Inc. (previously Ascent Therapeutics, Inc.) developing chemistry, analytical methods and formulations for the pepducin peptide technology. From 2008 to 2009 Dr. Houston served as vice president, chemistry & formulations at MDRNA, Inc., overseeing drug product processes and managing preclinical development. From 2004 to 2008 Dr. Houston served at Nastech Pharmaceutical Company Inc. in various leadership positions including senior director of chemistry and formulations. Prior to that, Dr. Houston has also served at Cytovax Biotechnologies, Inc. as director of chemistry and senior scientist, focusing on the development of peptide-protein conjugate vaccines. Dr. Houston received a B.Sc. in chemistry and a Ph.D. in bio-organic chemistry from the University of Waterloo, Ontario, Canada, and completed his post-doctoral fellowships in protein engineering at the Protein Engineering Network of Centres of Excellence at the University of Alberta.
- Shing Yin Tsui
Shing Yin Tsui自2015年12月起担任金融副总裁；2016年2月起担任秘书和首席会计官。加入公司之前，Tsui在Dendreon Corporation（一家生物技术公司）担任多个会计职位，包括从2014年到2015年担任副总裁和企业总监；2013年到2014年担任高级主管和企业总监；2011年到2013年担任会计运营和企业应用高级主管；1999年到2011年担任企业总监。在Dendreon Corporation任职期间，Tsui管理会计部门，包括准备与Dendreon Corporation首次公开上市和二次公共上市相关的文件；以及Sarbanes-Oxley Act合规项目的实施。
Shing Yin Tsui has served as our senior vice president of finance since July 2016 and as secretary and principal accounting officer since February 2016. Ms. Tsui joined us as our vice president, finance in December 2015. Prior to joining us, Ms. Tsui served in various accounting positions at Dendreon Corporation, a biotechnology company, including serving as vice president, corporate controller from 2014 to 2015 as senior director, corporate controller from 2013 to 2014 as senior director, accounting operations and enterprise applications from 2011 to 2013 and as corporate controller from 1999 to 2011. At Dendreon Corporation, Ms. Tsui managed the accounting department, including preparing publicly-filed documents in connection with the initial public offering and secondary public offerings by Dendreon Corporation and implementation of Sarbanes-Oxley Act compliance program. Ms. Tsui has over 20 years of financial management experience in Securities and Exchange Commission reporting, conducting mergers and acquisitions due diligence and accounting operations. Ms. Tsui holds a B.A. in business administration from the University of Washington and has passed the certified public accountant exam.- Shing Yin Tsui自2015年12月起担任金融副总裁；2016年2月起担任秘书和首席会计官。加入公司之前，Tsui在Dendreon Corporation（一家生物技术公司）担任多个会计职位，包括从2014年到2015年担任副总裁和企业总监；2013年到2014年担任高级主管和企业总监；2011年到2013年担任会计运营和企业应用高级主管；1999年到2011年担任企业总监。在Dendreon Corporation任职期间，Tsui管理会计部门，包括准备与Dendreon Corporation首次公开上市和二次公共上市相关的文件；以及Sarbanes-Oxley Act合规项目的实施。
- Shing Yin Tsui has served as our senior vice president of finance since July 2016 and as secretary and principal accounting officer since February 2016. Ms. Tsui joined us as our vice president, finance in December 2015. Prior to joining us, Ms. Tsui served in various accounting positions at Dendreon Corporation, a biotechnology company, including serving as vice president, corporate controller from 2014 to 2015 as senior director, corporate controller from 2013 to 2014 as senior director, accounting operations and enterprise applications from 2011 to 2013 and as corporate controller from 1999 to 2011. At Dendreon Corporation, Ms. Tsui managed the accounting department, including preparing publicly-filed documents in connection with the initial public offering and secondary public offerings by Dendreon Corporation and implementation of Sarbanes-Oxley Act compliance program. Ms. Tsui has over 20 years of financial management experience in Securities and Exchange Commission reporting, conducting mergers and acquisitions due diligence and accounting operations. Ms. Tsui holds a B.A. in business administration from the University of Washington and has passed the certified public accountant exam.
- Gordon Brandt
Gordon Brandt，医学博士，自2016年8月起担任我们的首席医疗官。在他被任命为我们的首席医疗官之前，Brandt博士从2012年开始担任我们的首席临床顾问。此前，他曾担任Nastech Pharmaceutical Company Inc.（后更名为MDRNA Inc.）的总裁兼临床研究和医疗事务执行Vice President，在那里他曾致力于核酸疗法的开发。此前，他曾任职Sonus Pharmaceuticals，Inc.（肿瘤药物开发商），在那里他曾担任Vice President、临床和监管事务以及医疗事务主管。Brandt博士毕业于耶鲁大学（Yale University），获得工程科学B.S.学位，在加州大学旧金山分校（University of California，San Francisco）获得医学博士学位，并在旧金山凯萨医院（Kaiser Hospital）完成内科住院医师培训。他在医疗器械、生物、药物领域工作了30多年，成功领导了美国和欧盟的药物审批项目。
Gordon Brandt, MD, has served as our chief medical officer since August 2016. Prior to his appointment as our chief medical officer, Dr. Brandt served as our chief clinical advisor from 2012. Prior to this, he served as president and executive vice president of clinical research and medical affairs for Nastech Pharmaceutical Company Inc. which became MDRNA Inc., where he worked to develop nucleic acid therapeutics. Previously, Dr. Brandt worked at Sonus Pharmaceuticals, Inc., a developer of oncology drugs, where he held the positions of vice president, clinical and regulatory affairs, and director of medical affairs. Dr. Brandt graduated from Yale University with a B.S. degree in engineering science, received an M.D. from the University of California, San Francisco, and completed his residency training in internal medicine at Kaiser Hospital in San Francisco. He has worked in the medical device, biologic, and drug fields for more than 30 years, and has successfully led both U.S. and EU drug approval programs.- Gordon Brandt，医学博士，自2016年8月起担任我们的首席医疗官。在他被任命为我们的首席医疗官之前，Brandt博士从2012年开始担任我们的首席临床顾问。此前，他曾担任Nastech Pharmaceutical Company Inc.（后更名为MDRNA Inc.）的总裁兼临床研究和医疗事务执行Vice President，在那里他曾致力于核酸疗法的开发。此前，他曾任职Sonus Pharmaceuticals，Inc.（肿瘤药物开发商），在那里他曾担任Vice President、临床和监管事务以及医疗事务主管。Brandt博士毕业于耶鲁大学（Yale University），获得工程科学B.S.学位，在加州大学旧金山分校（University of California，San Francisco）获得医学博士学位，并在旧金山凯萨医院（Kaiser Hospital）完成内科住院医师培训。他在医疗器械、生物、药物领域工作了30多年，成功领导了美国和欧盟的药物审批项目。
- Gordon Brandt, MD, has served as our chief medical officer since August 2016. Prior to his appointment as our chief medical officer, Dr. Brandt served as our chief clinical advisor from 2012. Prior to this, he served as president and executive vice president of clinical research and medical affairs for Nastech Pharmaceutical Company Inc. which became MDRNA Inc., where he worked to develop nucleic acid therapeutics. Previously, Dr. Brandt worked at Sonus Pharmaceuticals, Inc., a developer of oncology drugs, where he held the positions of vice president, clinical and regulatory affairs, and director of medical affairs. Dr. Brandt graduated from Yale University with a B.S. degree in engineering science, received an M.D. from the University of California, San Francisco, and completed his residency training in internal medicine at Kaiser Hospital in San Francisco. He has worked in the medical device, biologic, and drug fields for more than 30 years, and has successfully led both U.S. and EU drug approval programs.